Primary Immune Thrombocytopenia
Conditions
Brief summary
Complete response rate (CRR)/Partial response rate (PRR) at 6 months of treatment.
Detailed description
Patients with treatment-emergent adverse events (AEs) and serious AEs., Overall response rate at 2, 6 and 12 months., Complete response rate at 12 months., Time to response (TTR), Duration of response (DoR)., ORR., Number of participants with abnormal ocular findings (on ophthalmic exam)., Belantamab mafodotin dose holds., Number and proportion of participants with changes from baseline in ocular symptoms and related impacts as measured by the Vision Related Anamnestic Tool
Interventions
None listed
Sponsors
Hellenic Society Of Hematology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate (CRR)/Partial response rate (PRR) at 6 months of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients with treatment-emergent adverse events (AEs) and serious AEs., Overall response rate at 2, 6 and 12 months., Complete response rate at 12 months., Time to response (TTR), Duration of response (DoR)., ORR., Number of participants with abnormal ocular findings (on ophthalmic exam)., Belantamab mafodotin dose holds., Number and proportion of participants with changes from baseline in ocular symptoms and related impacts as measured by the Vision Related Anamnestic Tool | — |
Countries
Greece
Outcome results
None listed